Bronchopulmonary dysplasia, or BPD, is a chronic lung disease that develops when the fragile, immature lungs of very preterm infants are damaged by mechanical ventilation, oxygen therapy, and inflammation during the first weeks of life. Infants who develop BPD often require prolonged respiratory support and hospitalization, and they face elevated risks of rehospitalization, neurodevelopmental impairment, and long-term respiratory problems such as asthma-like symptoms and reduced lung function well into childhood and adulthood. Because survival rates for extremely preterm infants have climbed steadily over recent decades, BPD has become one of the most common long-term consequences of prematurity, making effective prevention strategies a major priority for neonatal medicine.

Caffeine is already a workhorse of neonatal care. A methylxanthine compound that crosses the blood-brain barrier readily, caffeine acts primarily as a respiratory stimulant by antagonizing adenosine receptors in the brainstem, increasing the drive to breathe and improving diaphragmatic contractility. Since a landmark 2006 international trial demonstrated that caffeine therapy shortened the duration of mechanical ventilation and reduced the rate of BPD among extremely low-birth-weight infants, caffeine citrate has become standard treatment for apnea of prematurity in neonatal intensive care units worldwide. However, that trial initiated caffeine only once apnea developed or clinicians judged treatment necessary—what neonatologists call therapeutic administration. Whether giving the drug prophylactically, within hours of birth to all very preterm infants regardless of symptoms, could prevent BPD more effectively remained unresolved, and prior smaller studies had produced mixed and inconclusive results.

To address this gap, researchers led by Fangfang Tao and Jiang-Qin Liu of Shanghai First Maternity and Infant Hospital, together with colleagues at Children’s Hospital of Fudan University and the University of Alberta, enrolled 372 very preterm neonates born before 32 weeks and 0 days of gestation between September 2016 and January 2024. In this single-center, randomized clinical trial, infants were assigned to one of two strategies. The prophylactic caffeine administration group received caffeine citrate shortly after birth, beginning with a loading dose of 20 milligrams per kilogram of body weight followed by a daily maintenance dose of 10 milligrams per kilogram. The comparison group received therapeutic caffeine administration, meaning the same drug at the same doses, but only after a diagnosis of apnea was made. The primary endpoint was the composite of BPD at 36 weeks postmenstrual age and/or death before hospital discharge.

The results favored early treatment. BPD or death occurred in 37.1 percent of infants in the prophylactic group—69 of 186 infants—compared with 47.3 percent in the therapeutic group, or 88 of 186. That difference corresponds to a relative risk of 0.77 with a 95 percent confidence interval of 0.62 to 0.95, and a P value of 0.013, meaning the reduction was statistically significant and unlikely to be due to chance alone. In practical terms, for roughly every ten very preterm infants treated prophylactically rather than reactively, one fewer infant would be expected to die before discharge or leave the hospital requiring oxygen for chronic lung disease.

The effect proved robust across five different sensitivity analysis models designed to test whether the finding depended on particular statistical assumptions. Notably, the benefit appeared more pronounced in several clinically meaningful subgroups: female infants, infants whose mothers had received antenatal corticosteroids to accelerate fetal lung maturation, infants who were not intubated in the delivery room, and infants who required only noninvasive ventilation after birth. This pattern is biologically plausible, since these are infants whose lungs were less severely compromised at the outset and who therefore stood to gain the most from protecting the airways and respiratory drive before injury could accumulate.

Caffeine’s protective mechanism in the context of BPD is thought to extend beyond simple respiratory stimulation. Experimental work suggests that caffeine exerts anti-inflammatory effects, modulates cytokine responses, improves diaphragmatic and intercostal muscle function, and enhances respiratory pattern stability, all of which can reduce the need for invasive mechanical ventilation and high oxygen concentrations—the principal drivers of lung injury in preterm infants. By stabilizing breathing from the first hours of life, prophylactic caffeine may prevent the cascade of apnea episodes, desaturations, and escalation of ventilatory support that culminates in chronic lung disease.

The trial was not without signals of potential harm, and the authors were careful to report them. Infants in the prophylactic group received a higher number of blood transfusions than those in the therapeutic group, with a mean difference of 0.42 transfusions (95 percent confidence interval, 0.05 to 0.79; P = 0.027). The clinical significance of this small increase is uncertain, but it aligns with earlier observations that early caffeine use has been associated with more frequent phlebotomy-related blood sampling and transfusion in previous trials. Importantly, no significant differences were observed between the two groups in the incidence of other serious complications of prematurity, including necrotizing enterocolitis, intraventricular hemorrhage, retinopathy of prematurity, and late-onset sepsis, nor in the duration of mechanical or noninvasive ventilation, oxygen exposure, length of hospital stay, or medical costs.

The researchers emphasized that the study had limitations inherent to its design. As a single-center trial, its findings may reflect the specific practices and patient population of one institution, and confirmation in multicenter settings is needed before the results can be generalized universally. The trial was registered retrospectively in the Chinese Clinical Trial Registry, a point the authors acknowledged transparently. In addition, the composite primary outcome of BPD or death, while standard in neonatal trials, combines two distinct events, and a larger sample would be required to separately power each component. Still, the trial’s seven-and-a-half-year enrollment window, its randomized design, and the consistency of the effect across sensitivity analyses lend considerable weight to the conclusion.

For neonatologists, the study raises the prospect of shifting practice: rather than waiting for apnea to declare itself, starting caffeine citrate routinely within the first hours of life in infants born before 32 weeks could prevent a substantial share of BPD cases and deaths. Prophylactic caffeine is already inexpensive, well tolerated, and familiar to every neonatal unit, which means that if the findings are confirmed, implementation barriers would be minimal compared with entirely new therapies. As BPD continues to burden a growing population of preterm survivors, an intervention this simple—administering earlier a drug already sitting in the NICU pharmacy—represents exactly the kind of low-cost, high-reach strategy that could reshape outcomes for the most vulnerable newborns. The study was funded through the CHINA-CANADA Clinical Research program, and the full open-access article is available in BMC Pediatrics.

Subject of Research: Prophylactic caffeine administration to prevent bronchopulmonary dysplasia in very preterm infants

Article Title: Prophylactic administration of caffeine reduces bronchopulmonary dysplasia in very preterm infants: a single center, randomized controlled trial

Article References: Tao, F., Zhou, M., Fu, Y., Zhou, J., Wang, M., Duan, Y., Li, M., Hua, J., Wang, Y., Chen, C., Cheung, P.-Y., Yuan, L., Yan, W., & Liu, J.-Q. (2026). Prophylactic administration of caffeine reduces bronchopulmonary dysplasia in very preterm infants: a single center, randomized controlled trial. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07625-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07625-5

Keywords: caffeine, bronchopulmonary dysplasia, very preterm infants, prophylactic administration, randomized controlled trial, apnea of prematurity, neonatal intensive care, caffeine citrate, chronic lung disease, mechanical ventilation, Prophylactic, administration

The investigative team meticulously searched leading medical databases including MEDLINE, CENTRAL, and EMBASE, gathering data from 25 pertinent studies. Out of these, six provided specific outcomes related to AKI, and among them, three adjusted observational studies were integrated into the meta-analysis. This analytical approach aimed to synthesize diverse datasets to generate a more robust estimation of caffeine’s efficacy and safety. Risk of bias and study quality were scrupulously appraised using the sophisticated RoB2 and ROBINS-I tools, while the overall confidence in the collective findings was rated with the GRADE framework, known for its stringent evidence evaluation.

The meta-analysis unveiled a striking association: neonates receiving caffeine early after birth exhibited an 84% reduction in the odds of developing acute kidney injury, reflected in an adjusted odds ratio (aOR) of 0.16. With a 95% confidence interval ranging from 0.09 to 0.31, these results suggest a pronounced and statistically significant protective effect. However, the certainty of this evidence was classified as low, indicating that while findings are promising, further high-quality randomized controlled trials are necessary to confirm these preliminary benefits conclusively.

Beyond the incidence of AKI itself, the researchers sought to determine whether caffeine influences biomarkers indicative of renal function deterioration. One clinical study included in the review, involving 50 neonates, reported on the maximum serum creatinine levels—a critical metric for kidney filtration capability. The findings hinted at a reduction in peak creatinine by 0.42 mg/dL in those treated with caffeine, a potential sign of improved renal preservation. Nonetheless, this evidence was tagged as very low certainty, underscoring the need for broader confirmatory research to understand caffeine’s impact on kidney function dynamics fully.

Safety remains paramount in neonatology, and the potential side effects of any intervention must be carefully weighed. Impressively, the pooled data from the included studies indicated no marked increase in adverse events associated with early caffeine administration. Though a formal meta-analysis of side effects could not be performed due to data limitations, qualitative assessments did not identify any new safety concerns, suggesting that caffeine’s well-established profile as a stimulant with known neonatal applications, such as apnea of prematurity, could extend safely into kidney injury prevention.

This synthesis of evidence resonates with the growing understanding that caffeine, a widely accessible and relatively inexpensive agent, may confer multifaceted benefits in critical neonatal care settings. The putative mechanisms might involve its known ability to improve renal blood flow and mitigate nephrotoxic stress, although the molecular pathways remain to be elucidated. These findings set a compelling stage for future mechanistic studies to decode the biological underpinnings of caffeine’s renal protective effects.

Importantly, this meta-analysis exemplifies the challenges and intricacies of neonatal research. Variability in study designs, differing definitions of AKI severity and timing, and heterogeneous patient populations all complicate the interpretation of pooled data. Despite these hurdles, the rigorous bias assessment strengthens confidence in the observed associations, providing clinicians and researchers with a valuable synthesis of current global evidence.

The implications for clinical practice could be substantial. Should subsequent randomized trials affirm these results, early caffeine administration may emerge as a standard prophylactic measure against AKI in vulnerable neonates. This advancement could reduce the burden of renal complications, lower intensive care durations, and improve long-term outcomes for infants most at risk. In contexts with limited access to advanced therapies, caffeine’s affordability and wide availability amplify its potential impact.

Moreover, the study invites a reevaluation of neonatal caffeine usage protocols, promoting a more nuanced approach that balances benefits beyond respiratory support. It challenges the community to broaden the therapeutic scope of caffeine, encouraging multidisciplinary collaborations to incorporate nephrology insights into neonatal care pathways.

The researchers advocate for large-scale, multicenter randomized controlled trials to solidify caffeine’s protective role and safety profile definitively. Such investigations should harmonize AKI definitions, standardize dosing regimens, and expand monitoring for potential adverse effects to produce actionable clinical guidelines. Meanwhile, clinicians are urged to consider these findings thoughtfully within the context of existing protocols and individual patient scenarios.

This systematic review and meta-analysis represent a pivotal moment in neonatal medicine, blending rigorous data synthesis with clinical relevance. It reiterates the importance of reexamining well-known substances through the lens of evolving scientific inquiry, unlocking new therapeutic potentials from familiar compounds. Caffeine, an ancient stimulant, may hold the key to a modern solution for one of neonatology’s most daunting challenges.

The study exemplifies the transformative power of integrating observational insights and controlled trial data to guide evidence-based practice. It highlights the need for continued vigilance in neonatal interventions’ safety, especially when repurposing common drugs for novel indications. Such research not only advances scientific understanding but also delivers hope to countless families confronting the uncertainties of neonatal critical illness.

Moving forward, the convergence of clinical expertise, translational research, and robust trial design will be essential to harness caffeine’s full potential in kidney protection and beyond. This study lays the groundwork for a new era where simple, accessible interventions can dramatically alter neonatal outcomes, shifting paradigms in neonatal intensive care units worldwide.

As neonatal morbidity remains a global health priority, this research brings fresh optimism about mitigating one of the most severe complications faced by newborns. It also underscores caffeine’s unique place in therapeutic strategies, transcending its conventional uses and joining the frontline defense in preserving neonatal renal function.

With the continued commitment of researchers, clinicians, and policymakers to such innovative investigations, the promise of safer, more effective neonatal care moves closer to reality. The first week of life may soon become a critical window where caffeine’s benefits are harnessed not only to prevent apnea but also to shield the delicate kidneys from injury, transforming the prognosis for the most vulnerable patients.

Subject of Research:
Neonatal acute kidney injury prevention through early caffeine administration.

Article Title:
Caffeine for the prevention of acute kidney injury in neonates: a systematic review and meta-analysis.

Article References:
Kobayashi, R., Nagao, E., Hirano, D. et al. Caffeine for the prevention of acute kidney injury in neonates: a systematic review and meta-analysis. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02697-8

Image Credits: AI Generated

DOI: 22 April 2026

Keywords: neonatal acute kidney injury, caffeine, kidney protection, neonatal care, systematic review, meta-analysis, serum creatinine, neonatal safety